Alyson Smith Email & Phone Number

New York, New York, Us

Bothell, Washington, Us

Bothell, Washington, Us

Bothell, Washington, Us

Missoula, Montana, Us

Managed immunology laboratory personnel (4 Sr. scientists) developing and testing multiple classes of novel innate immune modulating compounds. Managed work for a variety of external contract agencies while interfacing with external collaborators. Collaborated with leaders and cross-functional teams (synthetic chemistry, process chemistry and formulations) to develop and execute experimental plans to advance drug candidates to pre-IND. Oversaw design and development of novel business ideas for next generation immunomodulatory agents.o Helped orchestrate multiple collaborative research agreements and collaborations with several large pharma and biotech partnerso Managed several large, multi-team projects with external pharmaceutical company collaborators with on-time delivery of all milestones o Oversaw internal pre-clinical development of a novel set of innate immunodulating compounds resulting in patent filing

Missoula, Mt, Us

Designed experimental plans and managed laboratory scientists preforming in vitro and in vivo experiments to investigate new small molecule innate immune receptor agonists, including several TLR (7/8 and 4) and C-type lectin receptors, for development of novel adjuvants for use in next generation vaccines, as cancer immunotherapies and treatments for autoimmune disorders. o Work resulted in two first-author publications, several other co-author manuscriptso Listed as key investigator or PI/Co-PI on 3 grantso Listed as inventor on 3 patents

Brentford, Middlesex, Gb

Design and direct industrial research projects focused on developing and screening novel pathogen-recognition receptor agonist compounds as vaccine adjuvants for oncology and infectious diseases. Specifically, induction of CD4+ and CD8+ T cell responses induced by dendritic cell/APC activation by various antigen/adjuvant combinations. In depth knowledge of both the innate and adaptive immune response. • Lead and supervise immunology cell-based assay development team; both in-house team and external, academic collaborators o Generated many different engineered reporter cell lines for compound screening o Screened several different small-molecule immunomodulator compounds in various in vitro, cell-based assays (HEK reporter, ELISA/Luminex, FACS, DC:T cell co-culture)• Devised and generated initial data with a multi-disciplinary team (chemist and formulations scientist) to propose an innovative business idea to top management – novel cancer vaccine strategy; currently being patented • Co-wrote and edited the technical proposal for the now fully funded, multi-institutional, NIH adjuvant development grant BAA-NIAID-DAIT-NIHAI2013168 – $13.4 million/5 years • Technical and regulatory document writing and editing; presentation of data and research plans to internal and external entities on regular (monthly) basis

Rochester, Minnesota, Us

Conceived and led a multi-disciplinary research team to utilize patient-specific induced pluripotent stem (iPS) cells to regenerate hypertrophied ventricles in pediatric patients with a congenital heart disease called hypoplastic left heart syndrome (HLHS). Specifically, I developed and optimized a novel method to exploit the hypersensitivity of pluripotent stem cells to DNA damage-induced apoptosis to purge a therapeutic population of semi-differentiated cardiopoetic stem cells of the risk of tumor growth and augment the safety profile of these transplant-ready, bioengineered cells. • Named inventor on patent, filed December 2014• Authored a grant that secured $50K in funding for maximizing the cardiac reparative capacity of therapeutic stem cells by pharmacologically purging teratoma-forming cells • Mentored several summer and graduate students. • Learned and applied project management principles, and project management software, to enhance deliverables in basic research

Rochester, Minnesota, Us

Designed and executed research on discovery of novel post translational mechanisms of regulation of pro-apoptotic BH3-only proteins and determining how those mechanisms regulate induction of apoptosis in response to various small molecule antineoplastic agents in several cancer malignancies. Also analyzed effect of lymphoma-associated mutations in the anti-apoptotic protein Bcl-2 on response to certain small-molecule oncology drugs. • Experience using various molecular biology/biochemistry and human cellular biology techniques (siRNA, cloning/transgene expression, antibody production, flow cytometry, westerns, qPCR, etc.) to delineate pathways involved in oncogenic signaling and apoptosis • Studied lymphoid malignancies mechanism(s) of resistance to an anti-cancer agent• Trainee recipient of Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training grant (T32)

Laramie, Wy, Us

Genetic engineering, expression and mechanical testing of synthetic spider silk protein, transgenically produced in alfalfa and Arabidopsis. Analysis of the conserved N-terminal domains in major ampullate spidroin protein. • Recipient of National Science Foundation EPSCoR Undergraduate Research Fellowship, 3x

Ph.D., Molecular Pharmacology And Experimental Therapeutics

Bachelor Of Science, Molecular Biology And Chemistry